Company profile
PRECISION BIOSCIENCES INC
NASDAQ:DTILBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Cyclophosphamide | approved | — | 8 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04171843 | phase1 | terminated | 2020-04-30 | 2022-10-19 | Precision BioSciences, Inc. | A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma |
| NCT04649112 | phase1 | completed | 2021-06-16 | 2022-12-22 | Precision BioSciences, Inc. | Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies |
| NCT04030195 | phase1_2 | completed | 2020-03-24 | 2021-06-24 | Precision BioSciences, Inc. | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL |
| NCT07429240 | phase1_2 | recruiting | 2026-04-24 | 2029-11-01 | Precision BioSciences, Inc. | PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) |
| NCT06680232 | phase1 | recruiting | 2024-11-14 | 2026-12-01 | Precision BioSciences, Inc. | Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B |
FDA applications (0)
No records yet.